問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Neurology

更新時間:2023-09-19

賴冠霖
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

26Cases

2024-03-01 - 2027-11-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-08-01 - 2027-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-07-01 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-05-20 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2025-02-01 - 2027-12-31

Phase II

Completed
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)
  • Condition/Disease

    Myasthenia Gravis, Generalized

  • Test Drug

    DNTH103

Participate Sites
8Sites

Recruiting7Sites

Study ended1Sites

2025-10-01 - 2031-04-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-05-31 - 2026-12-31

Phase III

Completed
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
  • Condition/Disease

    Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  • Test Drug

    ALN-TTRSC02

Participate Sites
3Sites

Recruiting3Sites

2021-01-01 - 2029-07-31

Phase III

Active
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis
  • Condition/Disease

    Myasthenia Gravis

  • Test Drug

    Inebilizumab

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2021-07-14 - 2027-04-17

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-06-15 - 2029-09-30

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3